✦ LIBER ✦

Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab)

✍ Scribed by Prof. Gennaro D’Amato, Enrica Bucchioni…

Book ID: 120886252
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2006
Tongue: English
Weight: 92 KB
Volume: 5
Category: Article
ISSN: 1176-3450
DOI: 10.2165/00151829-200605060-00004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Omalizumab, anti-IgE recombinant humaniz

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

✍ Busse, William; Corren, Jonathan; Lanier, Bobby Quentin; McAlary, Margaret; Fowl 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 209 KB

251 Phase I study of anti-IgE recombinan

251 Phase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma

✍ CORREN, J; FROEHLICH, J; SCHOENHOFF, M; SPECTOR, S; RACHELEFSKY, G; SCHANKER, H; 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 124 KB

Efficacy of omalizumab, an anti-IgE anti

Efficacy of omalizumab, an anti-IgE antibody, in patients with concomitant moderate-severe allergic asthma and persistent allergic rhinitis*1

✍ DAHL, R 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 26 KB

Omalizumab, an Anti-IgE Monoclonal Antib

Omalizumab, an Anti-IgE Monoclonal Antibody, Demonstrates Long-Term Asthma Control, Safety and Tolerability in Patients with Severe Allergic Asthma

✍ Hébert, J.; Rolli, M.; Gao, J.; Reisner, C. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 159 KB

Effect of secukinumab, a fully human ant

Effect of secukinumab, a fully human anti–interleukin-17a monoclonal antibody on C-reactive protein levels in patients with moderate to severe plaque psoriasis: Result of a dose-ranging study

📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub